Prior studies report slightly lower prostate-specific antigen (PSA) levels among obese men. To understand this effect, we investigated the association between PSA and blood HbA1c, C-peptide, leptin and adiponectin levels in African-American (AA) (n ¼ 121) and Caucasian (CA) (n ¼ 121) men. Among AA men, PSA levels decreased with increasing C-peptide levels (PSA ¼ 0.99, 0.93, 0.75 and 0.53 ng ml À1 across quartiles of C-peptide, respectively; P trend ¼ 0.005). Among CA men, PSA levels decreased with increasing HbA1c (PSA ¼ 0.84, 0.73, 0.77 and 0.45 ng ml À1 across quartiles of HbA1c, respectively; P trend ¼ 0.005). This may suggest that metabolic disturbances related to metabolic syndrome or diabetes affect the ability to detect early-stage prostate cancer.
Introduction
Over 30% of the US adult male population has a body mass index (BMI) greater than 30 kg m À2 and is considered obese, 1 while prostate cancer remains the most common cancer diagnosis in the United States. 2 Adipose tissue may interact with multiple systems believed to have a role in prostate carcinogenesis, including CYP19 (aromatase) conversion of testosterone into estrogens and changes in immune, inflammatory and insulin responses (reviewed in Ribeiro 3 ). However, while obesity has been associated with prostate cancer mortality [4] [5] [6] [7] and prostate-specific antigen (PSA) recurrence following primary treatment, [8] [9] [10] the relationship between obesity and prostate cancer risk remains poorly understood. For example, several studies report that obesity is associated with the stage of cancer at detection, 11, 12 and a metaanalysis from MacInnis and English estimated that each 5-unit increase in BMI was associated with an approximate 5% increase in the risk of developing advanced prostate cancer. 12 Furthermore, clinical prostate cancer risk has been associated with the metabolic syndrome, 13, 14 centralized obesity, 15 leptin levels [16] [17] [18] and insulin resistance. 19, 20 However, several studies report no evidence of an association, [21] [22] [23] [24] [25] [26] [27] while others report that BMI is associated with reduced risk of prostate cancer, particularly low-grade tumors. [28] [29] [30] Finally, there is evidence that prostate cancer risk changes with time following a diabetes diagnosis, from an increased risk proximal to the diabetes diagnosis to a reduction in risk, 31, 32 perhaps related to diabetes treatment, disease progression or changes in prostate cancer screening practices with time following a diabetes diagnosis. 33, 34 Any association between obesity and the clinical procedures used to screen or detect prostate cancer may contribute to inconsistent results across different study populations or over time. Prostate cancer detection increased dramatically following United States Food and Drug Administration's approval of the PSA test, and now most prostate cancer cases are identified in response to a suspicious PSA test. 2 Among the many factors that may affect blood PSA levels, such as age and race, BMI has been associated with lower PSA levels among apparently healthy men without a history of prostate cancer. [35] [36] [37] Indeed, PSA expression is under androgen receptor regulation, and obesity and hyperinsulinemia are also associated with lower testosterone levels. [38] [39] [40] [41] [42] However, a prior study found no association between leptin or adiponectin and PSA among prostate cancer patients, 43, 44 and the component(s) of body adiposity as estimated by BMI that affect PSA levels and perhaps the ability to detect early-stage prostate cancer remain unclear.
Thus, the purpose of this study was to investigate the association between PSA levels and obesity-related biomarkers, including leptin, adiponectin, C-peptide and glycosylated hemoglobin (HbA1c), in Caucasian (CA) and African-American (AA) men. Given the inverse relationship between testosterone and insulin, we hypothesize a stronger inverse association between PSA and C-peptide compared to the other markers. Overall, these results may begin to separate the component of BMI mediating any change in PSA levels.
Methods

Participants
Detailed methods of the Southern Community Cohort Study (SCCS) have been reported, 45 and study information is also available at www.southerncommunitystudy.org. The SCCS is a prospective cohort investigation initiated in 2001, designed to identify the determinants of cancer incidence and mortality in a racially diverse population. Subjects visiting community health centers located throughout the southeastern United States were approached for recruitment. Subjects were eligible if they were between 40 and 79 years of age and had not been under treatment for cancer (except nonmelanoma skin cancer) within the past year. All SCCS protocols have been approved by Institutional Review Boards at Vanderbilt University Medical Center and Meharry Medical College.
In 2005, a pilot project was developed within the SCCS to conduct investigations of racial disparities in candidate blood biomarkers of cancer risk. 35 Random samples of 198 AA and 198 CA male participants (suitable for a 398-well assay plate) were selected from 5389 male SCCS cohort members with frozen-stored blood. Furthermore, sampling was stratified by categories of BMI (18.0-24.9, 25.0-29.9, 30.0-45.0) and cigarette smoking (never, former, current), such that AA and CA participants had similar BMI and smoking distributions. Complete data for blood PSA, race and described obesity biomarkers were available for 301 of these participants. We further excluded men reporting a prior prostate cancer (n ¼ 3) or a diabetes (n ¼ 55) diagnosis. One subject with a very low and highly influential PSA value (0.02 ng ml
À1
) in the analysis was excluded. No participants reported recent use of finasteride or dutasteride, or reported using herbal supplements believed to affect blood PSA levels, at the time of blood collection.
Data and sample collection
All SCCS participants provided written informed consent and completed a comprehensive, in-person, baseline interview administered by a trained interviewer. The computer-assisted interview included demographics, weight and height and a wide range of other potential cancer risk factors. A blood sample was collected from participants at recruitment. Blood samples were refrigerated immediately after collection, and then shipped cold on that day to Vanderbilt University. Blood was processed and stored-frozen on delivery, on average within 1.2 days (range 1-5 days) after collection. Blood samples had been frozen at À86 1C for an average of 1.7 years (s.d. ¼ 0.7 years; range: 5 months-3 years) prior to assay.
Laboratory assays
Total PSA levels in serum were assayed in the ToxMed Reference Laboratory at Meharry Medical College using an Abbott Axsym Immuno analyzer (Abbott Laboratories, Abbot Park, IL, USA). Leptin, adiponectin and Cpeptide were assayed in the Vanderbilt Endocrinology Laboratory by RIA (Luminex Corp., Austin, TX, USA). HbA1c was measured by ELISA assay in the Vanderbilt Clinical Chemistry Lab. All assays were performed in accordance with manufacturer protocols. Intra-assay CVs were 6.1, 6.9, 7.7 and 1.5% for leptin, adiponectin, C-peptide and HbA1c, respectively.
Data analyses
Prior to our primary analyses, we investigated the effect of time since last meal and time of blood collection on leptin, C-peptide, HbA1c, adiponectin and PSA levels. Descriptive cubic spline plots of each biomarker over time of day or time since last meal were developed, followed by regressing time parameters on each biomarker. We found no indication that PSA, leptin, adiponectin and Hba1c levels were affected by the time of blood collection or the time since last meal. However, Cpeptide levels were significantly associated with linear and quadratic variables representing the number of hours since eating (hours þ hours 2 ); thus, these parameters were controlled for in the primary analyses.
Spearman correlation coefficients estimated the relationship between BMI and each biomarker. Within CA or AA participants, adjusted PSA levels were calculated across categories of each biomarker using a linear model, while adjusting for age and time since a meal (hours þ hours 2 ). PSA values were natural log transformed prior to analysis, and geometric mean PSA values within quartile categories of each biomarker are reported. Adding a variable to also control for BMI or time of day of blood collection did not affect our results. Tests for trend were performed by the Wald statistic for the continuous biomarker variable in the full model. Additional analyses explored these associations within obese (BMIX30) or non-obese (BMIo30) men. Tests for interaction representing differences in slopes (b) for the association between PSA and each marker between race and BMI categories were evaluated by the significance of a cross-product term in a model that also included each main effect term.
Results
This study included 121 AA and 121 CA men aged between 40 and 78 years (Table 1) . AA participants had significantly higher adjusted PSA levels (AA: PSA ¼ 0.9 ng ml À1 , CA: PSA ¼ 0.7 ng ml À1 ; P ¼ 0.04). BMI was strongly correlated with leptin, and inversely correlated with adiponectin levels (Table 2) . Correlations between BMI and C-peptide or HbA1c were weaker and significant only within CA men or AA participants, respectively. Although AA and CA participants had a similar BMI, AA participants had lower overall C-peptide levels than CA participants (AA: C-peptide ¼ 1.79 ng ml À1 , CA: C-peptide ¼ 2.60 ng ml À1 ; Po0.01). Furthermore, there was a significant interaction Biomarkers of obesity and PSA JH Fowke et al between race and HbA1c levels ( Table 3 ), such that obese AA men had significantly higher HbA1c levels compared to obese CA men (P interaction ¼ 0.02). Table 4 summarizes adjusted PSA levels across categories of leptin, C-peptide, HbA1c or adiponectin within AA and CA participants. PSA did not significantly differ across leptin categories. Further stratification by BMI had little effect, although the strong correlation between BMI and leptin limited our ability to investigate trends between PSA and leptin within each BMI category. PSA levels were lower with either low or high adiponectin levels, and trend in PSA across adiponectin categories was not significant.
There was a significant interaction between race and C-peptide on PSA levels (P interaction ¼ 0.02). PSA levels decreased approximately 50% from the lowest to the highest C-peptide categories among AA men. In contrast, C-peptide was not associated with PSA levels among CA men. Addition of BMI to the model did not substantially change these results. This inverse trend among AA men was evident across BMI categories, although this association was statistically significant only among participants with a BMI of 30 or more.
Prostate-specific antigen levels decreased by almost 50% across the range of HbA1c categories within CA men. This was unchanged with the addition of BMI to the model. However, the association between HbA1c and PSA appeared to be stronger among CA men with a BMI of less than 30. The interaction between race and Hba1c was not significant (P interaction ¼ 0.42); however, we did not find any trend or pattern between HbA1c and PSA among AA participants. To investigate the possibility that participants with a pre-diabetic condition were contributing to this association, we excluded participants with an HbA1c greater than 7%. Results were essentially unchanged, with a significant association among nonobese CA participants To consider the independence of these markers on PSA, we included HbA1c, leptin, C-peptide and adiponectin in a single model that also controlled for age, time since last meal and BMI. Among CA men, HbA1c was the only biomarker significantly associated with logtransformed PSA levels (b ¼ À0.27 (À0.45, À0.08), P ¼ 0.006). Among AA men, C-peptide was the only biomarker significantly associated with log-transformed PSA (b ¼ À0.15 (À0.25, À0.05), P ¼ 0.003).
Discussion
Any relationship between obesity and prostate cancer detection may affect our ability to detect and treat men with early-stage prostate cancer. An association between Biomarkers of obesity and PSA JH Fowke et al obesity and PSA levels may also interfere with our ability to investigate the relationship between obesity and prostate cancer risk. Although we found little evidence for an association between PSA and leptin or adiponectin, PSA levels were approximately 50% lower among AA men with high versus low C-peptide levels. Similarly, PSA levels were approximately 50% lower across the range of HbA1c levels among CA men, although this relationship appeared to be restricted to men with a BMI of less than 30. Leptin and adiponectin are proteins secreted by adipocytes and were strongly correlated, either positively or negatively, respectively, with BMI. We found no association between leptin or adiponectin and PSA levels, similar to prior investigation of prostatectomy patients. 43, 44 This suggests that any relationship between obesity and PSA is not mediated by these adipokines.
C-peptide is produced by the pancreas in equimolar amounts to insulin, while HbA1c is a marker of average blood glucose concentration over the prior 3 months and used to monitor insulin control among diabetics. The inverse relationship between insulin and androgens has been recognized for some time, as men with low testosterone are prone to decreased lipolysis of the central abdominal fat, an adverse metabolic profile, insulin resistance, hyperinsulinemia and type II diabetes. [46] [47] [48] Alternatively, insulin is also associated with a decrease in hepatic sex hormone-binding globulin production, 49 perhaps increasing the levels of unbound and biologically available testosterone. However, it is possible that pituitary luteinizing hormone release also may decline subsequently through a feedback loop to lower testosterone synthesis and restore the balance between free and bound testosterone levels. 48 Several studies also have reported hyperinsulenemia or the metabolic syndrome associated with higher PSA levels, but this was believed to be mediated through the effects of obesity and insulin on increased prostate volume and benign prostatic hyperplasia. [50] [51] [52] [53] Thus, while the mechanisms linking C-peptide or HbA1c to PSA requires further investigation, the observed inverse relationships in this study are generally consistent with the previously reported inverse relationship between testosterone and insulin.
Unfortunately, much remains unknown regarding any differences in insulin and androgens interaction across race groups. Our observation that differences in HbA1c between obese and non-obese men are larger in AA men, while AA men may have somewhat lower C-peptide levels is consistent with the National Health and Nutrition Examination Survey analysis of young adults. 54 Variability in red blood cell persistence or genetic polymorphisms associated with glycosylation, steroid hormone metabolism or androgen receptor function across race may contribute to observations that PSA and HbA1c are associated in non-obese CA men. We may also speculate that C-peptide better reflects insulin activity in AA men more than in CA men, particularly . Categories defined at quartile values of marker for all subjects. *BMI and leptin were strongly correlated, and categories of leptin were collapsed as o11.3 or X11.3 ng ml
À1
. Therefore, P-trend values are for differences in PSA between the two categories.
Biomarkers of obesity and PSA JH Fowke et al if AA men have a lower insulin clearance rate and accelerated pancreatic b-cell deterioration as reported previously. 55 Further investigations of the race-specific relationships between steroid hormone levels, insulin activity and obesity are warranted.
To the extent that obesity is associated with pre-clinical diabetes or the metabolic syndrome in any population, our results may suggest that it is more difficult to detect an early-stage prostate cancer among obese men. This may be contributing to previously reported protective associations between prostate cancer and obesity or weight change. [28] [29] [30] It may be possible that insulinrelated PSA suppression is causing a delay in referral for diagnostic biopsy and lending the appearance of a protective association between obesity and prostate cancer. Alternatively, a delay in detecting prostate cancer may lead to an association between obesity and advanced-stage prostate cancer. Such patterns have been observed, 12 suggesting pathways potentially linking obesity to prostate cancer need to be investigated.
These results also add to the complexity in the association between diabetes and prostate cancer. Prostate cancer risk may increase near the time of a diabetes diagnosis, but then subsequently decreases. 31, 32 The relevance of diabetes medication, treatment responses or pancreatic b-cell deterioration in prostate carcinogenesis and prostate cancer detection remains poorly understood. However, protective associations between diabetes and prostate cancer has been observed primarily in studies conducted since approval of the PSA test, 34 while prostate cancer risk increases with insulin resistance or the metabolic syndrome in regions where PSA screening is less prevalent. 13, 14, 19 These observations, clearly circumstantial in nature, may suggest that our current screening modalities for the early detection of prostate cancer are less effective among diabetics.
Strengths of our study include inclusion of AA men and CA men simultaneously, and the consideration of multiple obesity-related biomarkers. We excluded participants previously diagnosed with diabetes, controlled for BMI and age, and evaluated potential systematic effects associated with blood collection. However, there are several limitations to this study, including the cross-sectional study design. Weight and height data were self-reported, although self-reported BMI was strongly correlated with blood leptin levels ( Table 2) . Our sample size could not adequately support exploration of the data stratified by both race and BMI, and these preliminary results require replication and should include an expanded biomarker panel reflecting insulin, obesity and steroid hormone levels. Finally, few participants had PSA levels in the range sufficient for referral to biopsy, and we were unable to evaluate the clinical significance of PSA suppression on prostate cancer detection.
In conclusion, we found that HbA1c and C-peptide were associated with lower PSA levels among CA or AA men. This suggests that factors related to insulin activity may be affecting PSA levels used to detect early-stage prostate cancer.
